1. Home
  2. EXAS vs KNSL Comparison

EXAS vs KNSL Comparison

Compare EXAS & KNSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EXAS
  • KNSL
  • Stock Information
  • Founded
  • EXAS 1995
  • KNSL 2009
  • Country
  • EXAS United States
  • KNSL United States
  • Employees
  • EXAS N/A
  • KNSL N/A
  • Industry
  • EXAS Medical Specialities
  • KNSL Property-Casualty Insurers
  • Sector
  • EXAS Health Care
  • KNSL Finance
  • Exchange
  • EXAS Nasdaq
  • KNSL Nasdaq
  • Market Cap
  • EXAS 11.0B
  • KNSL 9.1B
  • IPO Year
  • EXAS N/A
  • KNSL 2016
  • Fundamental
  • Price
  • EXAS $100.87
  • KNSL $367.94
  • Analyst Decision
  • EXAS Strong Buy
  • KNSL Buy
  • Analyst Count
  • EXAS 18
  • KNSL 9
  • Target Price
  • EXAS $72.44
  • KNSL $492.38
  • AVG Volume (30 Days)
  • EXAS 7.2M
  • KNSL 285.0K
  • Earning Date
  • EXAS 11-03-2025
  • KNSL 10-23-2025
  • Dividend Yield
  • EXAS N/A
  • KNSL 0.18%
  • EPS Growth
  • EXAS N/A
  • KNSL 16.09
  • EPS
  • EXAS N/A
  • KNSL 20.35
  • Revenue
  • EXAS $3,082,033,000.00
  • KNSL $1,802,839,000.00
  • Revenue This Year
  • EXAS $16.68
  • KNSL $19.18
  • Revenue Next Year
  • EXAS $12.36
  • KNSL $8.03
  • P/E Ratio
  • EXAS N/A
  • KNSL $18.20
  • Revenue Growth
  • EXAS 14.47
  • KNSL 18.10
  • 52 Week Low
  • EXAS $38.81
  • KNSL $363.14
  • 52 Week High
  • EXAS $101.87
  • KNSL $531.79
  • Technical
  • Relative Strength Index (RSI)
  • EXAS 91.11
  • KNSL 29.78
  • Support Level
  • EXAS $66.00
  • KNSL $387.50
  • Resistance Level
  • EXAS $69.08
  • KNSL $399.00
  • Average True Range (ATR)
  • EXAS 3.80
  • KNSL 10.41
  • MACD
  • EXAS 2.49
  • KNSL -0.85
  • Stochastic Oscillator
  • EXAS 97.30
  • KNSL 14.34

About EXAS Exact Sciences Corporation

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

About KNSL Kinsale Capital Group Inc.

Kinsale Capital Group Inc is an insurance holding company. The company is engaged in offering property, casualty, and specialty insurance products. It offers specialty insurance products for allied health, healthcare, life sciences, professional, and a public entity. The company operates in only one reportable segment which is the Excess and Surplus Lines Insurance segment, which includes commercial excess and surplus lines liability and property insurance products through its underwriting divisions. The company generates revenues in the form of premiums and investment income.

Share on Social Networks: